No catches, no fine print just unadulterated book loving, with your favourite books saved to your own digital bookshelf.
New members get entered into our monthly draw to win £100 to spend in your local bookshop Plus lots lots more…Find out more
While drug discovery for common disorders is somewhat standard and based on the large potential markets, the small market for most orphan diseases means that effective therapies are uncommon. With next generation DNA sequencing, the pace of inherited novel rare disease gene identification has increased markedly. Drug discovery for rare diseases is somewhat hampered by a lack of collaboration between academia and industry separating the necessary resources from skills. This volume discusses important aspects of orphan drug development such as regulatory affairs, public industry partnership, bench to bedside using examples of rare diseases, challenges of clinical trials and future directions.
|Publication date:||6th August 2019|
|Publisher:||Productivity Press an imprint of Taylor & Francis Inc|
|Categories:||Medical research, Pharmacology, Biochemistry,|
Dr. Farooq's research focuses on the identification and understanding of the molecular pathways to develop novel therapeutic strategies for neurodegenerative and neuromuscular diseases such as Spinal Muscular Atrophy (SMA), Duchene Muscular Atrophy and Myotonic Dystrophy. He is also a member for the collaborative team of clinicians/scientists at Children's Hospital of Eastern Ontario and other pediatric centers working on initiating a dose escalation trial utilizing FDA approved drug celecoxib for the treatment of human SMA. Dr. Farooq has worked along with Dr. MacKenzie and his team and his research activities are expanding on a wider scale to repurpose drugs for ...More About Mondher Toumi